Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 266 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not... December 9, 2021 Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer October 15, 2021 FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... September 24, 2024 Load more HOT NEWS Dame Deborah James: why do deeply personal stories resonate with us... Protective HPV Vaccine-Induced Antibody Titres Can Be Detected Up To 12... Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with... PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients...
